EUVIMEDEUVIMED entdecken
Crossref

Tracking and Cumulative Lifetime Exposure to IGF-I in 6459 Healthy Individuals and in SGA Children Treated With GH

Anna Sophie L Kjaer iD, Rikke Beck Jensen iD, Jørgen H Petersen iD, Allan Linneberg iD, Line Lund Kårhus iD, Louise Scheutz Henriksen iD, Trine Holm Johannsen iD, Katharina M Main iD, Andrew R Hoffman iD, Anders Juul iD

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgac605 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Anna Sophie L Kjaer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Growth and Reproduction, Copenhagen University Hospital-Rigshospitalet, Copenhagen DK-2100, Denmark. Hauptthemen laut MEDLINE: Human Growth Hormone, Infant, Small for Gestational Age, Insulin-Like Growth Factor I. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Supraphysiological serum insulin-like growth factor-I (IGF-I) concentrations have been a matter of concern in children treated with GH because high IGF-I levels were associated with risk of later disease in former epidemiological studies.

Objective

To determine whether a single IGF-I measurement reliably reflects lifetime IGF-I exposure we evaluated intraindividual longitudinal tracking of IGF-I and IGF-binding protein-3 (IGFBP-3) levels and we estimated cumulative lifetime exposure to IGF-I in healthy and GH-treated individuals.

Methods

We included 6459 healthy participants (cross-sectional = 5326; longitudinal = 1133) aged 0-76 years (9963 serum samples) and 9 patients born small-for-gestational-age (SGA) with 238 serum samples during GH treatment. Intraindividual tracking of IGF-I and IGFBP-3 (SD score [SDS]) was determined by intraclass correlation coefficients (ICCs). Cumulative lifetime IGF-I exposure was estimated by area under the curve of the predicted SDS trajectory from 0 to 76 years.

Results

For IGF-I (SDS), ICCs were 0.50 (95% CI, 0.47-0.53) for male and 0.53 (0.50-0.56) for female participants. Lifetime IGF-I exposure was significantly higher in female (mean 12 723 ± 3691 SD) than in male participants (12 563 ± 3393); P = 0.02. In SGA children, treatment with GH increased the lifetime exposure to IGF-I from 9512 ± 1889 to 11 271 ± 1689, corresponding to an increase in lifetime IGF-I trajectory from −0.89 SD ± 0.57 to −0.35 SD ± 0.49.

Conclusion

Because IGF-I and IGFBP-3 levels track throughout life, a single measurement reliably reflects lifetime exposure. GH therapy increased the lifetime exposure to IGF-I only slightly and it remained below the average lifetime exposure in the reference population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Growth HormoneInfant, Small for Gestational AgeInsulin-Like Growth Factor IChildFemaleHumansInfant, NewbornMaleCross-Sectional StudiesFetal Growth RetardationInsulin-Like Growth Factor Binding Protein 3

Stichwörter der Autor:innen

GH treatmentIGF-IIGFBP-3SGAshort stature

Substanzen

Human Growth HormoneInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor I

Autor:innen und Institutionen

  • Department of Growth and Reproduction, Copenhagen University Hospital-Rigshospitalet, Copenhagen DK-2100, Denmark.
  • International Research and Research Training Centre in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital-Rigshospitalet, Copenhagen DK-2100, Denmark.
  • Department of Medicine, VA Palo Alto Health Care System and Stanford University School of Medicine, Palo Alto CA-94304, USA.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen DK-2200, Denmark.
  • Section of Biostatistics, University of Copenhagen, Copenhagen DK-2200, Denmark.
  • Center for Clinical Research and Prevention, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Frederiksberg DK-2000, Denmark.

ORCID-Profile: Anna Sophie L Kjaer, Rikke Beck Jensen, Jørgen H Petersen, Allan Linneberg, Line Lund Kårhus, Louise Scheutz Henriksen, Trine Holm Johannsen, Katharina M Main, Andrew R Hoffman, Anders Juul

Zitieren

APA

Kjaer, A. S. L., Jensen, R. B., Petersen, J. H., Linneberg, A., Kårhus, L. L., Henriksen, L. S., Johannsen, T. H., Main, K. M., Hoffman, A. R., & Juul, A. (2023). Tracking and Cumulative Lifetime Exposure to IGF-I in 6459 Healthy Individuals and in SGA Children Treated With GH. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgac605

Vancouver

Kjaer ASL, Jensen RB, Petersen JH, Linneberg A, Kårhus LL, Henriksen LS, et al. Tracking and Cumulative Lifetime Exposure to IGF-I in 6459 Healthy Individuals and in SGA Children Treated With GH. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgac605

BibTeX
@article{Kjaer2023,
  author = {Kjaer, Anna Sophie L and Jensen, Rikke Beck and Petersen, Jørgen H and Linneberg, Allan and Kårhus, Line Lund and Henriksen, Louise Scheutz and Johannsen, Trine Holm and Main, Katharina M and Hoffman, Andrew R and Juul, Anders},
  title = {Tracking and Cumulative Lifetime Exposure to IGF-I in 6459 Healthy Individuals and in SGA Children Treated With GH},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgac605}
}
Kostenlos starten →